Gaurav Shah
CEO at Rocket Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Rocket Pharmaceuticals Inc., 3 years.
Chief executive roles
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 13, 2026 | Rocket Pharmaceuticals Inc. | Open-market sale | โ2,837 | $3.38 | $9,592 |
| May 21, 2026 | Rocket Pharmaceuticals Inc. | Option exercise | +76,490 | $1.69 | $129,268 |
| May 21, 2026 | Rocket Pharmaceuticals Inc. | Open-market sale | โ55,684 | $3.09 | $172,064 |
| May 19, 2026 | Rocket Pharmaceuticals Inc. | Open-market sale | โ2,409 | $3.01 | $7,251 |
| May 13, 2026 | Rocket Pharmaceuticals Inc. | Open-market sale | โ2,728 | $3.61 | $9,848 |
| Feb 18, 2026 | Rocket Pharmaceuticals Inc. | Open-market sale | โ5,990 | $3.34 | $20,007 |
| Feb 13, 2026 | Rocket Pharmaceuticals Inc. | Open-market sale | โ12,279 | $3.31 | $40,643 |
| Feb 11, 2026 | Rocket Pharmaceuticals Inc. | Grant or award | +286,028 | โ | โ |
| Nov 18, 2025 | Rocket Pharmaceuticals Inc. | Open-market sale | โ6,276 | $2.98 | $18,702 |
| Aug 18, 2025 | Rocket Pharmaceuticals Inc. | Shares withheld for tax | โ2,234 | $3.05 | $6,814 |
| May 20, 2025 | Rocket Pharmaceuticals Inc. | Open-market sale | โ2,253 | $6.45 | $14,532 |
| May 16, 2025 | Rocket Pharmaceuticals Inc. | Open-market sale | โ3,621 | $6.53 | $23,645 |
| Apr 10, 2025 | Rocket Pharmaceuticals Inc. | Open-market purchase | +20,000 | $5.08 | $101,600 |
| Feb 21, 2025 | Rocket Pharmaceuticals Inc. | Open-market sale | โ16,303 | $10.58 | $172,486 |
| Feb 11, 2025 | Rocket Pharmaceuticals Inc. | Grant or award | +81,655 | โ | โ |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.